Kedrion Biopharma Email Format

Kedrion Biopharma uses the firstinitiallast format, so Jane Smith would be jsmith@kedrion.com.

Kedrion Biopharma focuses on rare and ultra-rare diseases addressed through plasma-derived therapies, with core areas including immunodeficiencies, coagulation disorders, and neurological conditions. The company has three clinical trials progressing in parallel in 2026.

Kedrion Biopharma employs approximately 2,667 people worldwide and operates across markets including the United States, Turkey, Mexico, Germany, the UK, Italy, and Brazil. The US is the company's largest market, accounting for over 61% of revenues in 2026.

QIVIGY is Kedrion Biopharma's first fully proprietary 10% intravenous immunoglobulin therapy, FDA-approved for treating adults with primary humoral immunodeficiency. Kedrion activated a nationwide US distribution network for QIVIGY in 2026, expanding patient access through specialty pharmacies, infusion centers, and hospitals.

Kedrion Biopharma is led by Group CEO Ugo Di Francesco, alongside Group CFO Ulrike Becker and Chief Operating Officer Massimiliano Barberis. You can use Clay to find and verify current contact details for the Kedrion Biopharma leadership team before outreach.